New shot aims to stop Chemo's dangerous side effect

NCT ID NCT06521931

Completed Disease control Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and whether platelet counts stayed high enough during treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PN20
What this could lead to: If successful, this could lead to a new option to prevent dangerously low platelet counts caused by chemotherapy, reducing bleeding risks and treatment delays.
What could go wrong: This is an early Phase 1 trial with only 24 participants, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma neoplasm thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THROMBOCYTOPENIA

Contacts and locations

Locations

Affiliated Hospital of Hebei University

Baoding, Hebei, 071000, China
Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, 646000, China
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266057, China
The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, 471003, China
Yiyang Central Hospital

Yiyang, Hunan, 413099, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.